The promise and potential risks of tobacco-free nicotine pouches in harm reduction

This scoping review explores the implications of tobacco-free nicotine pouches (TFNPs) as part of tobacco harm reduction (THR) strategies. Unlike traditional tobacco products, TFNPs contain no tobacco leaf and do not involve combustion, thereby presenting a potentially lower-risk alternative for nicotine consumption. The investigation included peer-reviewed studies up to May 31, 2023, analyzing chemical profiles, toxicology, user behavior, and health outcomes.

Evidence indicates that TFNPs expose users to significantly fewer toxicants than traditional cigarettes and smokeless tobacco products such as snus. Studies showed that TFNPs are associated with lower levels of harmful constituents like nitrosamines and heavy metals, aligning them closer to nicotine replacement therapies (NRTs) in terms of reduced exposure risk. Toxicological evaluations support these findings, with TFNPs demonstrating minimal cytotoxicity and genotoxicity in comparison to cigarette smoke.

Behavioral research highlighted that TFNPs could aid adult smokers in transitioning away from combustible tobacco, although their effectiveness in achieving complete cessation remains under examination. TFNPs generally produce a lower nicotine blood concentration (Cmax) and slower absorption (Tmax) than cigarettes, potentially translating to a lower abuse liability. Data suggests their usage primarily appeals to current or former tobacco users, with limited uptake among non-smokers, particularly youth.

Despite these promising outcomes, long-term data on health impacts are still limited. Regulatory approaches vary globally, reflecting differing levels of acceptance and caution. This review underscores the need for further comprehensive studies to fully understand TFNPs' role in THR and inform regulations that balance public health benefits and risks.